TRIUMPH-1, SURMOUNT-1 and STEP 1 are placebo-controlled studies of different interventions. Their published figures belong to their own populations, regimens, follow-up and analyses.
Three programs, different study questions
SURMOUNT-5 provides a direct comparison of tirzepatide and semaglutide, while TRIUMPH-5 is the registered direct retatrutideātirzepatide comparison. These answer narrower questions than a three-drug ranking.
| Intervention | Trial | Follow-up | Mean weight reduction | Context |
|---|---|---|---|---|
| Retatrutide | TRIUMPH-1 | 80 weeks | 28.3% vs 2.2% placebo | Sponsor efficacy analysis; 12 mg arm |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 20.9% vs 3.1% placebo | 15 mg arm |
| Semaglutide | STEP 1 | 68 weeks | 14.9% vs 2.4% placebo | 2.4 mg arm |
These percentages come from separate trials. Their populations, study durations, analysis methods and placebo responses differ. In SURMOUNT-5, the direct tirzepatide and semaglutide comparison yielded 20.2% and 13.7% mean reductions, respectively, at 72 weeks.
How to interpret the evidence
A useful comparison puts each percentage next to its study name, population, follow-up and comparator.
Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.